Brazil health regulator cancels clinical study for Bharat Biotech vaccine
BRASILIA, July 26 (Reuters) – Brazilian health regulator Anvisa on Monday said it had canceled a clinical study for the Covaxin vaccine for COVID-19 developed by India’s Bharat Biotech, amid allegations of irregularities in the government’s efforts to buy millions of doses of the shot.
Bharat on Friday said it had terminated a memorandum of understanding with the local partner company acting as its intermediary in Brazil, with Anvisa saying on Monday that the trials could not go forward as a result and would be canceled.
Anvisa had previously suspended the trials temporarily.
